Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Selay Lam, MDBSc,FRCPC, Chai Wye Phua, MD FRCPC, Joy Mangel, MD FRCPC, Kang Howson-Jan, MD FRCPC, Brandon Dorland, NP, MSN, Karen Atkinson, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139635

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Eri Kawata, MDPhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MDMSc, Michael Levy, PhD, Stephanie Santos, Hanxin Lin, PhD, Chris Howlett, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-138654

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Efficacy of Oral Ribavirin in Respiratory Syncytial Virus Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Centre Experience

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Krista Biederman, BScPhm, Brandon Dorland, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142888

Published: 2020

Journal Articles

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

Eri Kawata, MDPhD, Benjamin Hedley, PhD, Benjamin Chin-Yee, MD, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MDMSc, Cyrus C. Hsia, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Ping Yang, PhD DABMGG, Michael Levy, PhD, Stephanie Santos, Chris Howlett, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138667

Published: 2020

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3375.

https://doi.org/10.1182/blood-2019-126893

Published: 2019

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MD MSc, Kang Howson-Jan, MD FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Benjamin Hedley, PhD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3438.

https://doi.org/10.1182/blood-2019-128507

Published: 2019

Journal Articles

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Dennis Dong Hwan Kim, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2019) 134 (Supplement_1): 1644.

https://doi.org/10.1182/blood-2019-128283

Published: 2019

Journal Articles

Erythropoietin in Elderly Patients with Anemia of Unknown Etiology

Zachary Gowanlock, BASc, Swetha Sriram, MD, Alison Martin, MD, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MD MSc

Blood (2015) 126 (23): 3346.

https://doi.org/10.1182/blood.V126.23.3346.3346

Published: 2015

Journal Articles

Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

Matthew Kang, BHSc, MD FRCPC, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MD MSc, Ian H. Chin-Yee, MD FRCPC, Kang Howson-Jan, MD, Maisam Abouzeenni, BHSc, Michael J. Kovacs, MD FRCPC, Cyrus C. Hsia, BSc, MD FRCPC

Blood (2014) 124 (21): 5527.

https://doi.org/10.1182/blood.V124.21.5527.5527

Published: 2014

Journal Articles

A Systematic Review Of The Role Of Erythropoietin In The Pathophysiology Of Anemia In Elderly Patients

Swetha Sriram, MD, Anargyros Xenocostas, MD, FRCPC, Alejandro Lazo-Langner, MD, MSc

Blood (2013) 122 (21): 3432.

https://doi.org/10.1182/blood.V122.21.3432.3432

Published: 2013

Journal Articles

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Rachel MA Kyle, BSc, Alejandro Lazo-Langner, MD, MSc, Anargyros Xenocostas, MD, FRCPC, Ian H. Chin-Yee, MD, FRCPC, Kang Howson-Jan, MD, David Sanford, MD, Cyrus C. Hsia, BSc, MD, FRCPC

Blood (2012) 120 (21): 4274.

https://doi.org/10.1182/blood.V120.21.4274.4274

Published: 2012

Journal Articles

A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma

Ahraaz Wyne, MD, Leslie Skeith, MD, Joy E. Mangel, MD, FRCPC, Anargyros Xenocostas, MD, FRCPC, Alejandro Lazo-Langner, MD, MSc

Blood (2011) 118 (21): 4987.

https://doi.org/10.1182/blood.V118.21.4987.4987

Published: 2011

Journal Articles

Pharmacokinetics of Dasatinib in a Patient with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Treatment with Anti-Tuberculosis Therapy

Michelle P. Zeller, MD, Jan H Beumer, Pharm. D., Ph.D., Susan M Christner, B.S., Anargyros Xenocostas, MD, FRCPC

Blood (2011) 118 (21): 5006.

https://doi.org/10.1182/blood.V118.21.5006.5006

Published: 2011

Journal Articles

Transfusion of Fresh but Not Stored Blood Reduces Infarct Size and Improves Cardiac Function Following Acute Myocardial Infarction In Anemic Rats

Anargyros Xenocostas, MD, FRCPC, Houxiang Hu, MD, Nicolas J Chin-Yee, Ian Chin-Yee, MD, FRCPC, Qingping Feng, MD, PhD

Blood (2010) 116 (21): 661.

https://doi.org/10.1182/blood.V116.21.661.661

Published: 2010

Journal Articles

Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells

Ruth M. Risueño, PhD, Eva Szabo, PhD, Uyen Maria Dang, BSc, Marilyne Levadoux-Martin, PhD, Jae-Uk Chung, Anargyros Xenocostas, MD, FRCPC, Brian Leber, MD, Mickie Bhatia, PhD

Blood (2010) 116 (21): 3278.

https://doi.org/10.1182/blood.V116.21.3278.3278

Published: 2010

Journal Articles

Recombinant Human Erythropoietin (rHuEPO) In Combination with Chemotherapy Increases Breast Cancer Metastasis In Pre-Clinical Mouse Models

Anargyros Xenocostas, MD, FRCPC, Benjamin D Hedley, PhD, Jenny E Chu, BSc, D. George Ormond, BSc, Michel Beausoleil, MSc, Alexandra Boasie, BSc, Alison L Allan, PhD

Blood (2010) 116 (21): 3345.

https://doi.org/10.1182/blood.V116.21.3345.3345

Published: 2010

NARROW

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Efficacy of Oral Ribavirin in Respiratory Syncytial Virus Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Centre Experience

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Erythropoietin in Elderly Patients with Anemia of Unknown Etiology

Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

A Systematic Review Of The Role Of Erythropoietin In The Pathophysiology Of Anemia In Elderly Patients

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma

Pharmacokinetics of Dasatinib in a Patient with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Treatment with Anti-Tuberculosis Therapy

Transfusion of Fresh but Not Stored Blood Reduces Infarct Size and Improves Cardiac Function Following Acute Myocardial Infarction In Anemic Rats

Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells

Recombinant Human Erythropoietin (rHuEPO) In Combination with Chemotherapy Increases Breast Cancer Metastasis In Pre-Clinical Mouse Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only